Your browser doesn't support javascript.
loading
Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease.
Ismaili, Lhassane; Refouvelet, Bernard; Benchekroun, Mohamed; Brogi, Simone; Brindisi, Margherita; Gemma, Sandra; Campiani, Giuseppe; Filipic, Slavica; Agbaba, Danica; Esteban, Gerard; Unzeta, Mercedes; Nikolic, Katarina; Butini, Stefania; Marco-Contelles, José.
Afiliación
  • Ismaili L; Neurosciences Intégratives et Cliniques EA 481, Laboratoire de Chimie Organique et Thérapeutique, UFR SMP, 19 rue Ambroise Paré, Université de Franche-Comté, Université Bourgogne Franche-Comté, CHRU Besançon, F-25000 Besançon, France. Electronic address: lhassane.ismaili@univ-fcomte.fr.
  • Refouvelet B; Neurosciences Intégratives et Cliniques EA 481, Laboratoire de Chimie Organique et Thérapeutique, UFR SMP, 19 rue Ambroise Paré, Université de Franche-Comté, Université Bourgogne Franche-Comté, CHRU Besançon, F-25000 Besançon, France.
  • Benchekroun M; Neurosciences Intégratives et Cliniques EA 481, Laboratoire de Chimie Organique et Thérapeutique, UFR SMP, 19 rue Ambroise Paré, Université de Franche-Comté, Université Bourgogne Franche-Comté, CHRU Besançon, F-25000 Besançon, France.
  • Brogi S; European Research Centre for Drug Discovery and Development (NatSynDrugs) and Department of Biotechnology, Chemistry and Pharmacy, Università di Siena, Via A. Moro, 53100 Siena, Italy.
  • Brindisi M; European Research Centre for Drug Discovery and Development (NatSynDrugs) and Department of Biotechnology, Chemistry and Pharmacy, Università di Siena, Via A. Moro, 53100 Siena, Italy.
  • Gemma S; European Research Centre for Drug Discovery and Development (NatSynDrugs) and Department of Biotechnology, Chemistry and Pharmacy, Università di Siena, Via A. Moro, 53100 Siena, Italy.
  • Campiani G; European Research Centre for Drug Discovery and Development (NatSynDrugs) and Department of Biotechnology, Chemistry and Pharmacy, Università di Siena, Via A. Moro, 53100 Siena, Italy.
  • Filipic S; Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia.
  • Agbaba D; Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia.
  • Esteban G; Departament de Bioquímica i Biologia Molecular, Facultat de Medicina, Institut de Neurociències, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
  • Unzeta M; Departament de Bioquímica i Biologia Molecular, Facultat de Medicina, Institut de Neurociències, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
  • Nikolic K; Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia. Electronic address: knikolic@pharmacy.bg.ac.rs.
  • Butini S; European Research Centre for Drug Discovery and Development (NatSynDrugs) and Department of Biotechnology, Chemistry and Pharmacy, Università di Siena, Via A. Moro, 53100 Siena, Italy. Electronic address: butini3@unisi.it.
  • Marco-Contelles J; Laboratory of Medicinal Chemistry (IQOG, CSIC), C/ Juan de la Cierva 3, 28006 Madrid, Spain. Electronic address: iqoc21@iqog.csic.es.
Prog Neurobiol ; 151: 4-34, 2017 04.
Article en En | MEDLINE | ID: mdl-26797191
Alzheimer's disease is a multifactorial and fatal neurodegenerative disorder characterized by decline of cholinergic function, deregulation of other neurotransmitter systems, ß-amyloid fibril deposition, and ß-amyloid oligomers formation. Based on the involvement of a relevant number of biological systems in Alzheimer's disease progression, multitarget compounds may enable therapeutic efficacy. Accordingly, compounds possessing, besides anticholinergic activity and ß-amyloid aggregation inhibition properties, metal chelating and/or nitric oxide releasing properties with additional antioxidant capacity were developed. Other targets relevant to Alzheimer's disease have also been considered in the last years for producing multitarget compounds such as ß-secretase, monoamino oxidases, serotonin receptors and sigma 1 receptors. The purpose of this review will be to highlight recent reports on the development of multitarget compounds for Alzheimer's disease published within the last years focusing on multifunctional ligands characterized by tacrine-like and donepezil-like structures.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperidinas / Tacrina / Inhibidores de la Colinesterasa / Enfermedad de Alzheimer / Indanos Límite: Animals / Humans Idioma: En Revista: Prog Neurobiol Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperidinas / Tacrina / Inhibidores de la Colinesterasa / Enfermedad de Alzheimer / Indanos Límite: Animals / Humans Idioma: En Revista: Prog Neurobiol Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido